KRAS G12C INHIBITORS

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein

is a single bond or a double bond;

Cy1 is selected from —C 5-12 cycloalkyl, 5- to 12-membered heterocyclyl, —C 6-12 aryl or 5- to 12-membered heteroaryl;

Cy2 is selected from 4- to 12-membered cycloalkyl or 4- to 12-membered heterocyclyl;

L 1 is selected from a single bond, —CO—NR a —, —NR a —CO—, —O—, —NR a —, —NR a (CH 2 ) m —, —S—, —(CH 2 ) m —, —O—(CH 2 ) m —, —O—CH(R a )—, —CH(R a )—, —CH(R a )(CH 2 ) m —, —(CH 2 ) m —O—, —CO—, —SO 2 —, cycloalkylene, oxetandiyl, tetrahydrofurandiyl, tetrahydropyrandiyl, azetidindiyl, pyrrilidindiyl, piperidindiyl, or piperizindiyl;

R 1 is selected from —H, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —NR b R c , —C 3-12 cycloalkyl, —C 3-12 heterocyclyl, —C 6-12 aryl, or —C 5-12 heteroaryl, each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-12 cycloalkyl, —C 3-12 heterocyclyl, —C 6-12 aryl, or —C 5-12 heteroaryl is optionally substituted with at least one R 6 ;

R 2 is selected from —H, —C 1-8 alkyl, —NR b R c , —C 3-12 cycloalkyl, 3- to 12-membered heterocyclyl, —C 6-12 aryl, or 5- to 12-membered heteroaryl, wherein each of said —C 3-12 cycloalkyl, 3- to 12-membered heterocyclyl, —C 6-12 aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one R 6 ;

R 6 , at each of its occurrences, is independently —C 1-8 alkyl, halogen, hydroxy, oxo, —C 1-8 alkoxy, —NR b R c , —C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6-12 aryl, or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 1-8 alkoxy, —C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6-12 aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one halogen, hydroxy, amino, —C 1-8 alkoxy, —NR b R c , —CN, cycloalkyl, heterocyclyl, aryl or heteroaryl;

R 3 is selected from hydrogen, halogen, oxo, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6-12 aryl, 5- to 8-membered heteroaryl, —OR a , —NR a R b or —CN, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6-12 aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one halogen, hydroxy, —C 1-8 alkoxy, —C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6-12 aryl, or 5- to 12-membered heteroaryl; or

two R 3 together with the atom(s) to which they are attached, form a 3- to 8-membered ring, said ring comprising 0, 1 or 2 additional heteroatom(s) independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s), said ring is optionally substituted with at least one halogen, hydroxy, amino, —C 1-8 alkyl, —C 1-8 alkoxy, —NR b R c , —CN, cycloalkyl, heterocyclyl, aryl or heteroaryl;

R 5 is selected from —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, oxo, —NR b R c , —CO—NR b R c , cycloalkyl, heterocyclyl, aryl, or heteroaryl, —(CH 2 ) m —CN, or hydrogen;

R 4 is selected from

 wherein each of R 4a , R 4b and R 4c is independently hydrogen, deuterium (D), cyano (CN), halogen, —OR a , —C 1-8 alkyl, —C 3-12 cycloalkyl, —C 3-12 heterocyclyl, —C 6-12 aryl, —C 5-12 heteroaryl, —NR b R c , or —CONR b R c , each of said —C 1-8 alkyl, —C 3-12 cycloalkyl, —C 3-12 heterocyclyl, —C 6-12 aryl or —C 5-12 heteroaryl is optionally substituted with at least one R 6 ;

wherein each of R a , R b and R c is independently hydrogen, deuterium (D), cyano (CN), halogen, hydroxy, —C 1-8 alkoxy, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-8 cycloalkyl, 3- to 12-membered heterocyclyl, aryl, heteroaryl, —NR d R e , or —CO—NR d R e , each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with R f ; or

optionally (R a and R b ), or (R a and R c ) together with the atom(s) to which they are attached, form a 4- to 6 membered ring, said ring is optionally substituted with at least one R g ;

each R f is selected from halogen, hydroxy, oxo, —C 1-8 alkoxy, —NR d R e , —CO—NR d R e , —NR d —CO—R e , cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of said —C 1-8 alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy or —C 1-4 alkyl;

R a , R e and R g are each independently hydrogen, deuterium (D), halogen, or —C 1-8 alkyl; each of said —C 1-8 alkyl is optionally substituted with at least one halogen, oxo, CF 3 or —COCH 3 ;

p, q and t are independently selected from 0, 1, 2, 3 or 4;

r is selected from 0, 1 or 2;

each m and n are independently 0, 1, 2, 3, 4, 5 or 6.

2 . The compound according to claim 1 , wherein Cy1 is selected from 6-, 7-, 8-, 9-, or 10-membered ring, wherein said ring is saturated or unsaturated ring comprising 0, 1 or 2 heteroatom(s) independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s).

3 . The compound according to claim 1 , wherein Cy1 is selected from naphthalene, benzene, benzopyrazole, pyridine, benzocyclopentane, benzothiazole, benzimidazole, indole, quinoline, isoquinoline, benzotetrahydrofuran, tetrahydroquinoline, tetrahydroisoquinoline, dihydroindole, 1,2-dihydronaphthalene, 1,4-dihydronaphthalene, or tetralin.

4 . The compound according to claim 1 , wherein R 3 is selected from hydrogen, F, Cl, Br, I, oxo, methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, benzopyrazole, —OH, —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —NH 2 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 or —CN, each of said methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, benzopyrazole is optionally substituted with at least one F, Cl, Br, I, OH, —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, or benzopyrazole.

5 . The compound according to claim 4 , wherein R 3 is selected from hydrogen, F, Cl, Br, I, oxo, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —CF 3 , cyclopropyl, cyclobutyl, cyclopentyl, —OH, —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —NH 2 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 or —CN.

6 . The compound according to claim 1 , wherein two R 3 together with the atom(s) to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered ring, said ring comprising 0, 1 or 2 additional heteroatom(s) independently selected from nitrogen or oxygen as ring member(s), said ring is optionally substituted with at least one F, Cl, Br, I, OH, NH 2 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 , —CN, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, phenyl, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, or benzopyrazole.

7 . The compound according to claim 6 , wherein two R together with the atom(s) to which they are attached, form a ring, said ring is selected from phenyl, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole or benzopyrazole, each of said phenyl, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole or benzopyrazole is optionally substituted with at least one F, Cl, Br, I, OH, NH 2 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 , or —CN.

8 . The compound according to claim 1 , wherein Cy1 is selected from

9 . The compound according to claim 1 , wherein

moiety is selected from

10 . The compound according to claim 1 , wherein Cy2 is selected from 6-, 7-, 8-, 9-, or 10-membered ring, said ring is saturated or unsaturated ring comprising 0, 1 or 2 additional heteroatom(s) independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member(s).

11 . The compound according to claim 10 , wherein Cy2 is selected from

wherein * Cy2 refers to the position attached to R 4 moiety, and ** Cy2 refers to the position attached to the

moiety.

12 . The compound according to claim 11 , wherein R 5 is selected from —H, methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, oxo, —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 , —CO—N(CH 3 ) 2 , —CO—N(C 2 H 5 ) 2 , —CO—N(C 3 H 7 ) 2 , —CO—N(C 4 H 9 ) 2 , —CO—N(CH 3 )C 2 H 5 , —CO—N(CH 3 )C 3 H 7 , —CO—N(CH 3 )C 4 H 9 , —CO—N(C 2 H 5 )C 3 H 7 , —CO—N(C 2 H 5 )C 4 H 9 , —CO—N(C 3 H 7 )C 4 H 9 , —CH 2 —CN, —(CH 2 ) 2 —CN, —(CH 2 ) 3 —CN; preferably methyl or —CH 2 —CN.

13 . The compound according to claim 1 , wherein R 4 is selected from

wherein each of R 4a , R 4b and R 4c is independently hydrogen, deuterium (D), cyano (CN), F, Cl, Br, I, hydroxy, —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 Hg, —OC 5 H 11 , methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, benzopyrazole, —NH 2 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 , —CO—NH 2 , —CO—N(CH 3 ) 2 , —CO—N(C 2 H 5 ) 2 , —CO—N(C 3 H 7 ) 2 , —CO—N(C 4 H 9 ) 2 , —CO—N(CH 3 )C 2 H 5 , —CO—N(CH 3 )C 3 H 7 , —CO—N(CH 3 )C 4 H 9 , —CO—N(C 2 H 5 )C 3 H 7 , —CO—N(C 2 H 5 )C 4 H 9 , or —CO—N(C 3 H 7 )C 4 H 9 , each of said methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, benzopyrazole is optionally substituted with R f ; each R f is selected from F, Cl, Br, I, oxo, hydroxy, —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —NH 2 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 , —CO—NH 2 , —CO—N(CH 3 ) 2 , —CO—N(C 2 H 5 ) 2 , —CO—N(C 3 H 7 ) 2 , —CO—N(C 4 H 9 ) 2 , —CO—N(CH 3 )C 2 H 5 , —CO—N(CH 3 )C 3 H 7 , —CO—N(CH 3 )C 4 H 9 , —CO—N(C 2 H 5 )C 3 H 7 , —CO—N(C 2 H 5 )C 4 H 9 , —CO—N(C 3 H 7 )C 4 H 9 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, pyrrole, imidazole, pyrazole, thiazole, thiophene, oxazole, pyridine, indole, quinoline, isoquinoline, benzimidazole, benzothiazole, or benzopyrazole.

14 . The compound according to claim 13 , wherein R 4 is selected from

15 . The compound according to claim 1 , wherein the

moiety is selected from

16 . The compound according to claim 1 , wherein R 1 is selected from —H, methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl, each of said methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl is optionally substituted with at least one R 6 .

17 . The compound according to claim 16 , wherein R 1 is selected from —H, methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl.

18 . The compound according to claim 1 , wherein R 2 is selected from —H, methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , or —N(C 3 H 7 )C 4 H 9 , each of said methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, azacyclopropyl, azacyclobutyl, tetrahydropyrrole, piperidine, piperazine, morpholine, propylene oxide, oxacyclobutane, oxacyclopentane, oxacyclohexane, —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 is optionally substituted with at least one R 6 .

19 . The compound according to claim 18 , wherein R 2 is selected from H, —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —N(C 4 H 9 ) 2 , —N(CH 3 )C 2 H 5 , —N(CH 3 )C 3 H 7 , —N(CH 3 )C 4 H 9 , —N(C 2 H 5 )C 3 H 7 , —N(C 2 H 5 )C 4 H 9 , —N(C 3 H 7 )C 4 H 9 ,

20 . The compound according to claim 1 , wherein the

moiety is selected from —H,

21 . The compound according to claim 1 , wherein r is 0, and is a single bond or a double bond; or r is 1, and is a single bond or a double bond.

22 . A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

23 . A pharmaceutical composition comprising the compound of claim 1 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

24 . A method of treating cancer in subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.